Replies to post #7570 on Pluristem Therapeutics Inc (PSTI)

[Scott999]

Points well taken Spidey thank you. I concede, I was a little harsh.

In the very least it will speed things up or at least can't hurt, regardless of the reason. And yes, the significance with regards to ARS is monumental. So speed it up any way you can.

One question I have is how costly it is to add sites. Is it minimal, or is it only when a patient becomes enrolled, in which case there would be minimal impact on cost. Any ideas on that one?

[midastouch017]

the greater and more imminent value I understand from this trial is that this will be able to provide the Human safety data on R18 that everyone keeps worrying about and would be submitted with the ARS macaque information.

As is announced in today's PR:

Pluristem’s PLX-R18 cells are in late-stage development as a treatment for acute radiation syndrome (ARS)

I do not see how the current Phase I trail could cast
any data on a much more advanced development!?
The dosage may very well be different, probably
some other indicators too.
[IMHO]